Previous 10 | Next 10 |
AMES, Iowa, July 30, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) (“NewLink Genetics” or the “Company”) today announced financial results for the second quarter ended June 30, 2019 and provided an update on clinical and corporate develo...
Gainers: Tarena International (NASDAQ: TEDU ) +38% . Outlook Therapeutics (NASDAQ: OTLK ) +30% . Exela Technologies (NASDAQ: XELA ) +23% . Neptune Wellness Solutions (NASDAQ: NEPT ) +15% . SilverCrest Metals (NYSEMKT: SILV ) +13% . NewLink Genetics Corporation (NASDAQ: NLNK ) +...
NLG802, a prodrug of indoximod, produced significantly higher pharmacokinetic (PK) exposure in patients compared to molar equivalent of indoximod while maintaining encouraging safety profile Notable response in 5 th line pancreatic cancer patient re-challenged with chemotherapy after ...
NewLink Genetics Corporation (NLNK) Q1 2019 Results Conference Call May 08, 2019 04:30 PM ET Company Participants Lisa Miller - Director of Investor Relations Charles Link - Chairman, Chief Executive Officer and Chief Scientific Officer Eugene Kennedy - Chief Medical Officer Ca...
NewLink Genetics (NASDAQ: NLNK ): Q1 GAAP EPS of -$0.27 beats by $0.03 . Revenue of $0.1M (-99.0% Y/Y) in-line. Press Release More news on: NewLink Genetics Corporation, Earnings news and commentary, Healthcare stocks news, ,
AMES, Iowa, May 08, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced financial results for the first quarter ended March 31, 2019 and provided an update on clinical activities. “We continued to make progress across our clinical programs this ...
AMES, Iowa, May 06, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that the company will participate in the following investor and medical conferences: Bank of America Merrill Lynch Global Health Care Conference 2019 on May 14-16 in Las Vegas ...
AMES, Iowa, April 24, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced it will host its first quarter 2019 conference call and webcast at 4:30 PM ET on Wednesday, May 8, 2019, to discuss its first quarter financial results and provide an update of...
Gainers: AVEO Pharmaceuticals (NASDAQ: AVEO ) +35% . ADMA Biologics (NASDAQ: ADMA ) +32% . Sangamo Therapeutics (NASDAQ: SGMO ) +27% . Castor Maritime (NASDAQ: CTRM ) +24% . EDAP TMS S.A. (NASDAQ: EDAP ) +23% . Riot Blockchain (NASDAQ: RIOT ) +22% . Vaccinex (NASDAQ: VCNX ) +1...
Energy Focus (NASDAQ: EFOI ) -52% on Q4 earnings . More news on: Energy Focus, Inc., Evoke Pharma, Inc., Apyx Medical Corporation, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Kahn Swick & Foti, LLC Announces Summary Notice of Proposed Settlement Involving Purchasers of NewLink Common Stock Kahn Swick & Foti, LLC Announces Summary Notice of Proposed Settlement Involving Purchasers of NewLink Common Stock PR Newswire NEW ORLEANS ...
AUSTIN, Texas, March 30, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, has announced the appointment of Joseph S. McCracken, DVM, MS to the company's Board of Directors, effective March 23...
- Combined company, Lumos Pharma, Inc., to trade on Nasdaq under the stock symbol “LUMO” - Phase 2b trial expected to be initiated mid-2020 evaluating oral therapeutic candidate LUM-201 (ibutamoren) in Pediatric Growth Hormone Deficiency (PGHD) - Projected combined cash ...